Invivyd (NASDAQ:IVVD) Insider Sells $25,793.04 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 30,706 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total transaction of $25,793.04. Following the sale, the insider directly owned 283,774 shares in the company, valued at $238,370.16. The trade was a 9.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jill Andersen also recently made the following trade(s):

• On Monday, August 17th, Jill Andersen sold 37,256 shares of Invivyd stock. The stock was sold at an average price of $0.72, for a total transaction of $26,824.32.

Invivyd Stock Up 17.2%

Shares of NASDAQ IVVD traded up $0.13 on Tuesday, reaching $0.87. 7,732,095 shares of the company’s stock traded hands, compared to its average volume of 3,061,089. The business’s 50 day simple moving average is $0.77 and its two-hundred day simple moving average is $1.23. Invivyd, Inc. has a 12 month low of $0.48 and a 12 month high of $3.07. The company has a market cap of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The company had revenue of $14.29 million during the quarter, compared to the consensus estimate of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. Analysts forecast that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Wall Street Zen lowered Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Invivyd in a research report on Tuesday. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $8.00.

Hedge Funds Weigh In On Invivyd

A number of hedge funds have recently added to or reduced their stakes in IVVD. Courier Capital LLC bought a new position in Invivyd in the 4th quarter valued at approximately $25,000. Bronte Capital Management Pty Ltd. purchased a new stake in Invivyd during the 4th quarter valued at $27,000. DRW Securities LLC bought a new stake in shares of Invivyd in the 4th quarter worth $27,000. ProShare Advisors LLC purchased a new position in shares of Invivyd in the fourth quarter worth $30,000. Finally, State of Wyoming purchased a new position in shares of Invivyd in the fourth quarter worth $30,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.